Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NRX Pharmaceuticals Inc NRXP

Financial Services Healthcare
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of... see more

Recent & Breaking News (NDAQ:NRXP)

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

PR Newswire February 26, 2024

NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024

PR Newswire February 26, 2024

NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024

PR Newswire February 20, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)

PR Newswire February 12, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report

PR Newswire February 9, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon

PR Newswire February 5, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

PR Newswire January 22, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination

PR Newswire January 17, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

PR Newswire January 16, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco

PR Newswire January 2, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard

PR Newswire January 2, 2024

NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors

PR Newswire December 27, 2023

NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression

PR Newswire December 19, 2023

NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

PR Newswire December 18, 2023

NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders

PR Newswire December 13, 2023

NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event

PR Newswire December 11, 2023

NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference

PR Newswire November 27, 2023

NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

PR Newswire November 13, 2023

NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023

PR Newswire November 7, 2023

NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression

PR Newswire November 6, 2023